Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.64 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.64 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.64 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.61 |
| ▸ | FAP | Q12884 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16578291 | 1.00 | DPP4 (0.64) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6824150 | 1.00 | DPP4 (0.64) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL16710010 | 1.00 | DPP4 (0.64) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL5649501 | 0.98 | DPP4 (0.66) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL355114 | 0.98 | DPP4 (0.66) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL297708 | 0.98 | DPP4 (0.66) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL27616477 | 0.96 | DPP4 (0.64) | DPP4DPP8DPP9DPP7FAP | |
| Trifluoroacetic Acid SCHEMBL6923872 | 0.87 | DPP4 (0.67) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL3628073 | 0.82 | DPP4 (0.60) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL5966905 | 0.82 | DPP4 (0.60) | DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004076434-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | AIC (BE) | 2004-09-10 | — | — | WO | claimed |
| WO-2004076433-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | AIC (BE) | 2004-09-10 | — | — | WO | claimed |
| US-9242938-B2 | Glycine reuptake inhibitor and use thereof | BEIJING MEDISAN TECHNOLOGY CO., LTD (CN) | 2016-01-26 | — | — | US | disclosed |
| US-20150133497-A1 | GLYCINE REUPTAKE INHIBITOR AND USE THEREOF | BEIJING MEDISAN TECHNOLOGY CO., LTD. (CN) | 2015-05-14 | — | — | US | disclosed |
| WO-2004076434-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | AIC (BE) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133497-A1 | GLYCINE REUPTAKE INHIBITOR AND USE THEREOF | SLC6A2, SLC6A5, SLC6A4 | DPP4 2440/4885DPP8 3341/4885DPP9 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.